AstraZeneca's Phase 3 EMERALD-3 trial demonstrated that the STRIDE regimen, combining immunotherapy drugs Imfinzi and Imjudo with lenvatinib and TACE, significantly improved progression-free survival by 30% compared to TACE alone in patients with unresectable liver cancer. The median progression-free survival reached 13 months versus 9.8 months for TACE-only patients, with a positive trend also seen in overall survival. These results support advancing the STRIDE regimen to earlier treatment stages, addressing the need for better systemic therapies in liver cancer. The trial will continue to monitor overall survival and other endpoints.
At ASCO 2026, European pharma firms had a quiet showing, but AstraZeneca and Roche faced key challenges. AstraZeneca's lung cancer drug Datroway competes with Merck's sac-TMT, which showed strong efficacy but high toxicity, making AstraZeneca's bioma...
Citi views the upcoming phase three trial results for AstraZeneca's heart drug Wainua as favorable, expecting positive outcomes that could significantly boost sales. Wainua targets ATTR-cardiomyopathy by suppressing transthyretin protein production, ...
CelLBxHealth PLC has signed a master services agreement with AstraZeneca, enabling it to provide circulating tumour cell (CTC) analytics for AstraZeneca's drug discovery and development. Using its Parsortix platform, CelLBxHealth will analyze CTCs fr...
